## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.5% in mid entry zone (3.0-6.0%), top 7% cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Strong momentum (+2.3% 5-day acceleration). Outperforming sector by 4.1%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($995.98)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Eli Lilly & Co. cuts price of popular diabetes and weight-loss drugs in Canada**
- Source: The Globe and Mail | 20251218T040755 | Neutral | Relevance: 100%
- Eli Lilly & Co. is significantly reducing the prices of its diabetes and weight-loss drugs, Mounjaro and Zepbound, in Canada by 20% or more, effective December 29th. This move comes in anticipation of new federal pricing regulations and the imminent entry of generic Ozempic into the Canadian market. This strategic cut aims to realign pricing and compete in a rapidly evolving pharmaceutical landscape.

**2. Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Eli Lilly and Company (NYSE:LLY)**
- Source: MarketBeat | 20251218T010937 | Bullish | Relevance: 100%
- Representative Gilbert Ray Cisneros, Jr. (D-California) recently disclosed a purchase of between $1,001 and $15,000 in Eli Lilly and Company (NYSE:LLY) stock. This transaction, made on November 18th in his "150 MAIN STREET TRUST > BANK OF AMERICA" account, was made public on December 15th. Eli Lilly has reported strong financial results, including significant revenue growth and a raised quarterly dividend, while maintaining an average "Buy" rating from analysts with a consensus price target of $1,141.73.

**3. Scotiabank remains bullish on Eli Lilly and Company (LLY)**
- Source: MSN | 20251216T040803 | Bullish | Relevance: 100%
- Scotiabank reiterates its Outperform rating on Eli Lilly and Company (LLY). The firm emphasizes that despite the current valuation, significant potential remains due to the anticipated launch of multiple new products across large therapeutic areas, particularly with the expanding market of obesity drugs like Zepbound.

**4. Scotiabank Remains Bullish on Eli Lilly and Company (LLY)**
- Source: Finviz | 20251216T035318 | Bullish | Relevance: 99%
- Scotiabank has reiterated a Buy rating on Eli Lilly and Company (LLY) with a price target of $1,165.00, following positive Phase 3 clinical trial results for their investigational drug retatrutide. The drug demonstrated significant weight loss and relief from osteoarthritis pain in adults with obesity or overweight. The company anticipates completing seven additional Phase 3 trials for retatrutide in obesity and type 2 diabetes by 2026.

**5. Obesity data, Kymera and FDA sentiment survey results â€” a BioCentury podcast**
- Source: BioCentury | 20251216T013900 | Somewhat-Bullish | Relevance: 93%
- This BioCentury podcast discusses recent developments in the biotech industry, focusing on new obesity drug data from Eli Lilly, Structure Therapeutics, and Wave Life Sciences, alongside a Pfizer deal in the weight loss space. It also covers Kymera Therapeutics' data for its STAT6 program and the results of BioCentury's industry sentiment survey on the FDA, highlighting concerns about politicization and uncertainty.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($2.06M) |
| Sells | 28 ($172.80M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $173M sold (28 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 32.5x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (6 raises, avg +12%). Insider selling cluster ($172.8M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $947.4B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 32.5 |
| Current P/E | 44.7 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.2% to 4.5% (+2.3% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 0.8% confirms short-term momentum alignment. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-4.09), momentum weakening. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.52% (CS: 93) | Strong |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | -4.09 | Bearish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.293x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $1056.80
- **Stop Loss:** $995.98 (5.8% risk)
- **Target:** $1148.03 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 15
- **Position Value:** $15,852.00
- **Portfolio %:** 15.85%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*